Roche (VTX:ROG)

Roche is a Swiss pharmaceutical group, founded in 1896 by Fritz Hoffmann-La Roche, among the world leaders in the sector. Like Novartis, one of its main competitors, its headquarters is located in Basel, Switzerland. The company is the world leader in cancer medication and virology. It markets some famous products such as Valium, Xenical and the famous Tamiflu. Roche is present in 150 countries and now owns Genentech, an American laboratory specializing in biotechnologies.

The title offers an interesting long-term yield, at 3.24%, which it owes in particular to a very sustained growth rate of its distributions (20.88% in the medium term). Roche has been able to increase its dividend for 16 consecutive years, which is not bad, but not comparable to some of our giants. portfolio. The impressive growth of the dividend in recent years has had an impact on the distribution ratio, which currently stands at 59.35%. This remains, however, within reasonable proportions and allows the company to ensure the payment of its dividend in the future, even in the event of a difficult transition. volatility of the title is quite high (compared to our standards), since it amounts to 17,57%, significantly more than its competitor Novartis (11,69%).

Roche has been added to our portfolio, as part of our currency diversification strategy. It still falls short of certain criteria, which means that it is currently in observation phase (or in "hold" for those who already have it), but it is a value which has a certain number of qualities and which we wish to follow in the future.